A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea

• Status: Completed
• Trial end date: 2016-05-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a phaseIV, multicenter, open-label，single arm study which will be performed to evaluate efficacy and safety of Ceftriaxone sodium and Sulbactam Sodium for injection for the treatment of uncomplicated urogenital infection caused by Neisseria gonorrhoeae in adolescent and adult subjects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xiangbei Welman Pharmaceutical Co., Ltd
• Treatments: Ceftriaxone; Sulbactam

Criteria

Inclusion Criteria:

• Subjects must be >=6 or ≦80 years of age at the time of signing the informed consent,both gender

• Subjects having clinical suspicion of a urogenital gonococcal infection with or without gonococcal infection according to the laboratory test results of symptoms, physical symptoms, gonococcus smear, culture, etc.

• Subjects having clinical suspicion of a gonococcal infection must have both of the following risk factors:once used three generations of cephalosporin invalid, and sensitive to this product (including gonorrhea urethritis, cervicitis, proctitis, pharyngitis).

• Male and female subject must agree to use contraception (male condoms) during intercourse from the Baseline Visit through completion of the TOC Visit.

Exclusion Criteria:

• Subject has a history of sensitivity to the study treatments, or components thereof, or a history of a drug (including erythromycin and any macrolide or ketolide drug) or other allergy that, in the opinion of the investigator or medical monitor, contraindicates his or her participation

• Subject has received any cephalosporinl therapy for the treatment of a gonococcal infection

• Pregnant or lactating women, or women Subject of childbearing age who were unwilling or unable to use acceptable methods of contraception throughout the study period.

• Famale subject who were positive for pregnancy tests at the time of inclusion or before the start of study drug use.

• Subject has risk of potentially serious drug interactions

• Subject has major diseases such as cardiovascular disease, hepatorenal disease and mental disease, or other factors, the researcher should not participate in the study according to comprehensive judgment

• Subject has a known history of alcohol or drug abuse

• Subject has a known any complicated or systemic gonorrhea infection, such as pelvic inflammatory disease, arthritis, endocarditis